Compound News and Research

RSS

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

XJB-5-131 compound suppresses symptoms of Huntington's in mice

There's new hope in the fight against Huntington's disease. A group of researchers that includes scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have designed a compound that suppresses symptoms of the devastating disease in mice.

2 Nov 2012

Apolipoprotein E plays a major role in maintaining arterial softness

Arterial stiffening has long been considered a major risk factor for cardiovascular disease. Keeping arteries soft and supple might reduce disease risk, but the mechanisms of how arteries stave off hardening has remained elusive.

2 Nov 2012

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Omeros Corporation today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.

1 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Vitamin D and multiple sclerosis: an interview with Ellen Mowry

Vitamin D is actually a hormone. For the most part, humans obtain vitamin D through sun exposure. Ultraviolet light from the sun promotes the conversion of a compound in the skin to pre-vitamin D.

31 Oct 2012

Pins made of single atoms to fight cancer

Answers are often elusive in the fight against cancer, and Rice University chemist Zachary Ball is hoping to pin one down -- with pins made of single atoms. The work, which aims to create a drug that's effective against an "undruggable" protein, is one of the first 50 proposals funded under the National Cancer Institute's (NCI) Provocative Questions Project.

31 Oct 2012

Triapine shows promise in treating breast cancer

Students at Tennessee Tech University are developing and testing a series of chemical compounds that show promise of stopping cancer in its tracks.

29 Oct 2012

New therapy to treat rare form of cystic fibrosis works in unconventional way, scientists say

Scientists at the Hospital for Sick Children in Toronto have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis works in an unconventional way.

29 Oct 2012

Study demonstrates role of IRX4204 in alleviating cognitive decline in animal models of AD

New research presented in October at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer's disease (AD).

29 Oct 2012

Moms and babies more likely to die when co-ICU arises

When mothers and newborns are both admitted to intensive care units they are significantly more likely to die than when neither is admitted to an ICU, new research has found.

23 Oct 2012

Researchers increase potency of a compound that reactivates antibiotics against MRSA

Researchers from North Carolina State University have increased the potency of a compound that reactivates antibiotics against methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant form of Staphylococcus that is notoriously difficult to treat. Their improved compound removes the bacteria's antibiotic resistance and allows the antibiotic to once again become effective at normal dosage levels.

23 Oct 2012

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA.

22 Oct 2012

Novel C-substituted diindolylmethane shows promise against triple-negative breast cancer

A new compound created from a rich source in vegetables including broccoli and brussel sprouts has been developed to combat triple-negative breast cancer (TNBC).

19 Oct 2012

Minnelide gives new hope for patients with pancreatic cancer

A new drug created at the University of Minnesota may hold the answer to defeating pancreatic cancer, according to results published today in the prestigious journal Science Translational Medicine.

19 Oct 2012

BioResearch Open Access explores Cell-SELEX technology

SELEX is a rapid, efficient, and iterative high-throughput method for screening large libraries of molecules to identify those with the potential to be developed as drug compounds or research tools. Advances in SELEX technology that have enabled screening in live cells, called Cell-SELEX, are explored in a comprehensive Review article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.

19 Oct 2012

Compound News and Research

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

XJB-5-131 compound suppresses symptoms of Huntington's in mice

Apolipoprotein E plays a major role in maintaining arterial softness

Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's

Scientists discover first selective inhibitors of DAGL enzymes

Vitamin D and multiple sclerosis: an interview with Ellen Mowry

Pins made of single atoms to fight cancer

Triapine shows promise in treating breast cancer

New therapy to treat rare form of cystic fibrosis works in unconventional way, scientists say

Study demonstrates role of IRX4204 in alleviating cognitive decline in animal models of AD

Moms and babies more likely to die when co-ICU arises

Researchers increase potency of a compound that reactivates antibiotics against MRSA

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

Novel C-substituted diindolylmethane shows promise against triple-negative breast cancer

Minnelide gives new hope for patients with pancreatic cancer

BioResearch Open Access explores Cell-SELEX technology

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News